Dermatological Drugs: World Market Prospects 2013-2023
Report Details
Your guide to revenue prospects for the treatment of skin diseases
What's the commercial outlook for treating skin disorders? Visiongain's updated report gives you forecasted revenues to 2023 and also explains R&D trends, outlooks and opportunities.
Our study lets you assess sales data for the world market, therapeutic submarkets, products and national markets. It shows you that industry's most promising and lucrative segments.
Forecasts and other analyses to help you stay ahead in knowledge
The report gives you revenue forecasts to 2023, historical data, growth rates and market shares. Also, it lets you see qualitative analysis (SWOT and STEP), business outlooks and developmental trends (R&D). You gain 99 tables, 61 charts and two research interviews.
Is finding commercial details a challenge? Our report helps you get ahead in knowledge, benefiting your research, analyses and decisions. Find trends, innovations and opportunities. You see what's happening.
There's rising demand for dermal medicines. Discover areas of the market that will prosper, reducing the risk of your being left behind.
The following sections show how you benefit from our new study.
Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you see forecasts to 2023 for these five submarkets:
See revenue forecasts for products
How will leading drugs perform to 2023 at world level? Our study forecasts sales of 23 products, including these brands:
Our analysis also breaks the main world forecast into geographical markets.
What prospects for leading countries?
Developments worldwide will influence the market, especially rising demand in emerging countries, especially China and India. Our report shows outlooks for the industry.
You see individual forecasts to 2023 for eleven national markets, finding overall revenues:
Our analyses show growth will occur in established pharma markets and in developing countries. In particular, drug launches from 2013 to 2023 will change the world market.
Research and development - assess innovation, trends and possibilities
What about R&D - the pipeline for new drugs? You see trends for these areas:
What affects that industry and market?
Our report discusses issues and events affecting dermatological medicine from 2013:
Leading companies and 2015 market value
Our study predicts the overall world market for drugs treating skin disorders will reach $24.4bn in 2015, and expand further to 2023.
Our study shows you what products and organisations hold greatest potential. It discusses these companies:
Prospects for R&D are strong, and from 2013 onwards there will arise many opportunities. Our work shows you the technological and commercial possibilities, helping you stay ahead.
Nine ways Dermatological Drugs: World Market Prospects 2013-2023 helps
To sum up, our investigation gives you the following knowledge:
That work gives independent analysis. You receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.
With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, also saving time and getting you recognition for insight.
Discover technological and commercial prospects from 2013 by ordering now
Our investigation is for everyone needing analysis of the industry and market for treating skin conditions. There you find data, trends and predictions. Please order our report now.
Your guide to revenue prospects for the treatment of skin diseases
What's the commercial outlook for treating skin disorders? Visiongain's updated report gives you forecasted revenues to 2023 and also explains R&D trends, outlooks and opportunities.
Our study lets you assess sales data for the world market, therapeutic submarkets, products and national markets. It shows you that industry's most promising and lucrative segments.
Forecasts and other analyses to help you stay ahead in knowledge
The report gives you revenue forecasts to 2023, historical data, growth rates and market shares. Also, it lets you see qualitative analysis (SWOT and STEP), business outlooks and developmental trends (R&D). You gain 99 tables, 61 charts and two research interviews.
Is finding commercial details a challenge? Our report helps you get ahead in knowledge, benefiting your research, analyses and decisions. Find trends, innovations and opportunities. You see what's happening.
There's rising demand for dermal medicines. Discover areas of the market that will prosper, reducing the risk of your being left behind.
The following sections show how you benefit from our new study.
Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you see forecasts to 2023 for these five submarkets:
- Infectious skin disease
- Psoriasis
- Dermatitis
- Acne
- Other treatments.
See revenue forecasts for products
How will leading drugs perform to 2023 at world level? Our study forecasts sales of 23 products, including these brands:
- Cubicin
- Zyvox
- Humira
- Enbrel
- Stelara
- Claravis
- Epiduo
- Protopic.
Our analysis also breaks the main world forecast into geographical markets.
What prospects for leading countries?
Developments worldwide will influence the market, especially rising demand in emerging countries, especially China and India. Our report shows outlooks for the industry.
You see individual forecasts to 2023 for eleven national markets, finding overall revenues:
- US
- Japan
- Germany, France, UK, Italy and Spain (EU5)
- Brazil, Russia, India and China (BRIC).
Our analyses show growth will occur in established pharma markets and in developing countries. In particular, drug launches from 2013 to 2023 will change the world market.
Research and development - assess innovation, trends and possibilities
What about R&D - the pipeline for new drugs? You see trends for these areas:
- Skin infections
- Dermatitis
- Acne
- Other progress in dermatology.
- Drug delivery
- Oral drug candidates
- TNF antagonism and calcineurin inhibition
- Novel small molecules
- Photodynamic therapy.
What affects that industry and market?
Our report discusses issues and events affecting dermatological medicine from 2013:
- Reformulations and combination therapies
- Generic competition and new drug classes
- Needs for antibacterial, antiviral and antifungal treatments
- Patient compliance
- Rx-to-OTC switching.
- Biological drugs (e.g., monoclonal antibodies), biosimilars and follow-on biologics
- Hospital-acquired infections and drug-resistant bacteria
- Anti-inflammatory agents
- Topical and systemic treatments
- Opportunities for specialty pharma companies and small biotechs.
Leading companies and 2015 market value
Our study predicts the overall world market for drugs treating skin disorders will reach $24.4bn in 2015, and expand further to 2023.
Our study shows you what products and organisations hold greatest potential. It discusses these companies:
- Pfizer
- GSK
- Abbott
- Johnson & Johnson
- Takeda
- Roche
- Merck & Co.
- Galderma
- Cubist Pharmaceuticals
- Teva
- LEO Pharma
- Astellas
- Novartis.
Prospects for R&D are strong, and from 2013 onwards there will arise many opportunities. Our work shows you the technological and commercial possibilities, helping you stay ahead.
Nine ways Dermatological Drugs: World Market Prospects 2013-2023 helps
To sum up, our investigation gives you the following knowledge:
- Revenues to 2023 for the overall world market and five main submarkets - you discover that industry's prospects
- Revenues to 2023 for 23 leading products - you find sales outlooks for top drugs
- Forecasts to 2023 for US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China - you see national sales potentials
- Assessments of companies - you find activities, products, capabilities and outlooks
- Review of R&D - you hear about progress in dermatological research and development, finding technological and medical possibilities
- Interviews with authorities in dermatology and the related pharmaceutical industry - you discover debates and opinions to help you stay ahead
- Competition and opportunities - you see what affects that industry, learning what shapes its future
- Analysis of what stimulates and restrains the industry and market - you assess challenges and strengths, helping you compete and gain advantages
- Prospects for established firms and those seeking to enter the sector - you explore needs, practices and outlooks for success.
That work gives independent analysis. You receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.
With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, also saving time and getting you recognition for insight.
Discover technological and commercial prospects from 2013 by ordering now
Our investigation is for everyone needing analysis of the industry and market for treating skin conditions. There you find data, trends and predictions. Please order our report now.
1. EXECUTIVE SUMMARY
1.1 World Dermatological Drug Market: Overview of Findings
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods
2. INTRODUCTION TO DERMATOLOGICAL DISORDERS AND THEIR TREATMENTS
2.1 An Introduction to Dermatology
2.1.1 The Structure of the Skin, Hair and Nails
2.1.2 Sweat and Sebaceous Glands
2.2 Functions of the Skin
2.3 Common Skin Diseases
2.4 An Introduction to Acne Vulgaris
2.4.1 Causes of Acne
2.5 An Introduction to Dermatitis - Inflammation of the Skin
2.5.1 Atopic Dermatitis
2.5.2 Contact Dermatitis
2.5.3 Seborrheic Dermatitis
2.5.4 Nummular Dermatitis
2.5.5 Perioral Dermatitis
2.6 An Introduction to Psoriasis - A Complex Multifactorial Disease
2.7 An Introduction to Rosacea - Vascular Instability
2.8 An Introduction to Alopecia - The Excessive Shedding of Hair
2.9 An Introduction to Infectious Diseases of the Skin - A Serious Healthcare Threat
2.9.1 Bacterial Skin Infections
2.9.2 Fungal Skin Infections
2.9.3 Viral Skin Infections
2.10 Common Skin Treatments
2.10.1 Creams and Semisolid Emulsions
2.10.2 Ointments
2.10.3 Lotions
2.10.4 Solutions
2.10.5 Occlusive Therapy
2.10.6 Cleansing Agents
2.10.7 Powders and Hydrophilic Polymer
2.10.8 Anti-Infective Agents
2.10.9 Anti-Inflammatory Agents
3. THE WORLD DERMATOLOGICAL DRUG MARKET 2013-2023
3.1 The World Dermatological Drug Market 2011
3.1.1 The Infectious Skin Disease Market Dominates
3.2 The World Dermatological Drug Market: Forecasts 2012-2023
3.2.1 Market Shares for Leading Segments - Psoriasis Market Grows
3.2.2 Biologic Agents for the Treatment of Psoriasis Are the Leading Drugs in the Dermatologics Market
3.3 The Future of the Dermatological Drug Market
3.3.1 Opportunities for Blockbuster Sales
4. THE INFECTIOUS SKIN DISEASES DRUG MARKET 2013-2023
4.1 The Infectious Skin Diseases Drug Market 2011
4.1.1 Antibacterial Products Led the Dermatological Infectious Skin Diseases Market in 2011
4.2 World Infectious Skin Diseases Drug Market Forecast 2012-2023
4.3 Cubicin (Daptomycin, Cubist Pharmaceuticals)
4.3.1 Cubicin: Revenue Forecast 2012-2023
4.4 Zyvox (Linezolid, Pfizer)
4.4.1 Zyvox: Revenue Forecast 2012-2023
4.4.1.1 Zyvox: Patent Expiry and Generic Competition
4.5 Valtrex (Valacyclovir, GSK)
4.5.1 Patent Expiry and the End of Blockbuster Revenues
4.5.2 Valtrex Sales Continue to Decline - Increased Generic Competition
4.6 Zovirax (Acyclovir, Valeant/GSK)
4.6.1 Zovirax Sales Forecast 2012-2023
4.7 Bactroban (Mupirocin, GSK)
4.7.1 Bactroban Sales Forecast 2012-2023
4.8 Lamisil (Terbinafine, Novartis)
4.8.1 Lamisil Sales Forecast 2012-2023 - Growth in Emerging Markets
4.9 Aldara (Imiquimod, Valeant/Meda AB)
4.9.1 Reformulation and Zyclara Development
4.9.2 Aldara Sales Forecast, 2012-2023
4.10 The Infectious Skin Diseases Market - Summary
5. THE PSORIASIS DRUG MARKET 2013-2023
5.1 The Psoriasis Drug Market in 2011 - Biologic Drugs Led
5.1.1 Side-Effects of Biologics
5.2 World Psoriasis Drug Market Forecast 2012-2023
5.2.1 Growth Driven by Increasing Use of Biologics
5.3 Humira (Adalimumab, Abbott)
5.3.1 Humira Market Analysis and Forecast 2012-2023
5.3.2 Humira Sales Continue to Grow
5.3.3 Long-Term Prospects for Humira
5.4 Enbrel (Etanercept, Amgen/Pfizer/Takeda)
5.4.1 Enbrel Sales, 2011
5.4.2 Enbrel Sales Will Show an Initial Increase
5.4.3 Study Eases Fears of TNF Blocker Cancer Risk
5.4.4 New Enbrel Delivery System
5.4.5 Sales of Enbrel will Eventually Decline
5.4.6 Enbrel Faces Competition from Several Other Biotech Drugs
5.4.7 Biosimilar and Pipeline Competition
5.5 Stelara (Ustekinumab, Johnson & Johnson)
5.5.1 Stelara Advantages Promote Sales Growth
5.6 Remicade (Infliximab, Johnson & Johnson)
5.6.1 Remicade Psoriasis Market Forecast 2012-2023
5.7 Daivobet/Dovobet/Taclonex (Calcipotriol and Betamethasone, LEO Pharma) - Topical Treatments for Psoriasis
5.7.1 Daivobet/Dovobet/Taclonex - Generic Competition?
5.7.2 Daivobet Sales Prospects
5.8 The World Psoriasis Drug Market - Summary
6. THE DERMATITIS DRUG MARKET 2013-2023
6.1 The Dermatitis Drug Market in 2011
6.1.1 Corticosteroids are the Leading Dermatitis Treatment
6.2 Dermatitis Drug Market Forecast 2012-2023
6.3 Protopic (Tacrolimus, Astellas/Roche)
6.3.1 Protopic Sales Forecast 2012-2023
6.3.1.1 Protopic Benefits from Expanded Indication
6.3.1.2 Generic Competition Will Erode Sales
6.4 Elidel (Pimecrolimus, Novartis/Meda AB/Valeant)
6.4.1 Acquisition of Elidel Marketing Rights
6.4.2 Regulatory Developments
6.4.3 Elidel Sales Growth Stimulated
6.5 Elocon (Mometasone Furoate, Merck & Co.)
6.5.1 Elocon Sales Forecast 2012-2023
6.6 Clob X/Clobex (Clobetasol Propionate, Galderma)
6.6.1 Clobex Sales Face Generic Competition
6.7 The Dermatitis Drug Market - Summary
7. THE ACNE DRUG MARKET 2013-2023
7.1 Leading Products in the Acne Drug Market 2011
7.2 World Acne Drug Market Forecast 2012-2023
7.3 Claravis (Isotretinoin, Teva)
7.3.1 Claravis Sales Forecast 2012-2023
7.3.2 Competition from New Formulations
7.4 Solodyn (Minocycline, Valeant/Medicis)
7.4.1 Solodyn - A Leading Acne Treatment
7.4.2 Solodyn Sales Forecast 2012-2023
7.5 Diane (Cyproterone and Ethinylestradiol, Bayer): Market Analysis and Forecast 2012-2023
7.6 Duac (Clindamycin and Benzoyl Peroxide, GSK) - Generic Competition Erodes Sales
7.7 Doryx (Doxycycline Hyclate, Warner Chilcott/Mayne)
7.7.1 Lifecycle Management and Generic Competition
7.7.2 Doryx Sales Forecast 2012-2023
7.8 Differin (Adapalene, Galderma)
7.8.1 Lifecycle Management of Galderma's Adapalene Products
7.8.2 Differin Sales Forecast 2012-2023
7.9 Combination Treatments for Acne
7.10 Epiduo (Adapalene and Benzoyl Peroxide, Galderma)
7.10.1 Epiduo Forecast 2012-2023
7.11 Ziana (Tretinoin and Clindamycin, Valeant/Medicis)
7.12 Veltin (Tretinoin and Clindamycin, GSK)
7.13 The World Acne Drug Market - Summary
8. NATIONAL MARKET FORECASTS 2013-2023
8.1 Leading National Markets for Dermatological Drugs 2011
8.2 Leading National Markets for Dermatological Drugs: Forecasts 2012-2023
8.3 The Dermatological Drug Market in the US: Market Forecast 2012-2023
8.4 EU5 Dermatological Drug Markets 2012-2023
8.4.1 The Dermatological Drug Market in Germany: Market Forecast 2012-2023
8.4.2 The Dermatological Drug Market in France: Market Forecast 2012-2023
8.4.3 The Dermatological Drug Market in the UK: Market Forecast 2012-2023
8.4.4 The Dermatological Drug Market in Italy: Market Forecast 2012-2023
8.4.5 The Dermatological Drug Market in Spain: Market Forecast 2012-2023
8.5 The Dermatological Drug Market in Japan: Market Forecast 2012-2023
8.6 The Dermatological Drug Market in China: Market Forecast 2012-2023
8.7 The Dermatological Drug Market in India: Market Forecast 2012-2023
8.8 The Dermatological Drug Market in Russia: Market Forecast 2012-2023
8.9 The Dermatological Drug Market in Brazil: Market Forecast 2012-2023
9. THE R&D PIPELINE FOR DERMATOLOGICAL PHARMACEUTICALS, 2013
9.1The Size of the Dermatological Pharmaceuticals Market Encourages R&D
9.1.1 New Technology in R&D Pipeline Activities
9.1.2 Reformulation
9.1.3 Combination Treatments
9.1.4 New Mechanisms and Drug Delivery Technologies
9.1.5 Potential Market Entrants
9.2 The Infectious Skin Disease Pipeline
9.2.1 NB-001( NanoBio Corporation)
9.2.2 Dalbavancin (Durata Therapeutics) - Promising Anti-bacterial Skin Infection Treatment
9.2.3 Nuvocid (Oritavancin)
9.2.4 Tedizolid (Trius Therapeutics) - Driver for Growth
9.3 The Psoriasis Pipeline
9.3.1 Briakinumab (Abbott)
9.3.2 XelJanz (Tofacitinib, Pfizer) - Leading Oral Candidate
9.3.3 Voclosporin (VCS, ISA247, Isotechnika/Lux Biosciences) - Novel Calcineurin Inhibitor
9.3.4 Apremilast (Celgene) - The Next TNF Antagonist to be Approved?
9.3.5 AS101 (BioMAS)
9.3.6 AIN457 (Secukinumab, Novartis) - A New Mechanism of Action?
9.3.7 ASP015K (Astellas/Janssen Biotech)
9.4 The Dermatitis Pipeline
9.4.1 LAS41002 (Almirall) - European Approval?
9.4.2 AN2728 (Anacor Pharmaceuticals) - A Novel Small Molecule
9.4.3 MRX6 (Morria Biopharmaceuticals)
9.5 The Acne Pipeline
9.5.1 Visonac (PhotoCure) - Photodynamic Therapy
9.5.2 Acne Vaccine - A Treatment for the Future?
9.6 The Miscellaneous Dermatological Drugs Pipeline
9.6.1 LAS 41005 (Actikeral, Almirall) - European Launch
9.6.2 Picato (PEP005, LEO Pharma)
9.7 Innovation Rules for Early-Stage Pipeline Drugs
10. QUALITATIVE ANALYSIS OF THE WORLD DERMATOLOGICAL DRUG MARKET, 2013
10.1 SWOT Analysis
10.2 Market Drivers
10.3 Market Restraints
10.4 Strengths and Opportunities
10.4.1 Opportunities for Market Development and Expansion
10.4.2 Advances in Research Will Boost Market
10.4.3 What Benefits Can OTC Switching Offer?
10.4.4 Growth in Skin Structure Infection Therapeutics
10.4.5 The Challenge and Opportunity: Hospital-Acquired Infections
10.4.6 Targeting Drug-Resistant Bacteria in Infectious Skin Diseases
10.4.7 Opportunities for Speciality Pharma and Small Biotechs
10.4.8 CROs Can Increase Dermatological Drug Development Speed to Market
10.5 Weaknesses and Threats
10.5.1 Competition in the Dermatological Drug Market Will Intensify
10.5.2 Threat of Substitutes
10.5.3 How Great is the Threat of Generic Drugs in the Dermatological Sector?
10.5.4 Patent Expiries Will Lead to Generic Competition
10.5.5 Vaccines for Preventing Infections, Opportunity or Threat?
10.6 STEP Analysis
10.6.1 Social Factors
10.6.1.1 Increased Healthcare Demands
10.6.1.2 Improving Patient Compliance is Vital
10.6.2 Technological
10.6.2.1 Personalised Dermatology: Technological Advances in Genomics
10.6.2.2 Advances in Topical Drug Delivery Methods
10.6.3 Economic Pressures
10.6.3.1 Reimbursement will Continue to Slide
10.6.3.2 Cutting Back Pharma R&D
10.6.3.3 Public Funding for Infectious Skin Disease Drug Development
10.6.4 Political
10.6.4.1 Downward Pressures on Drug Prices Affect the Industry
10.6.4.2 Increased Development Funding in the US for Infectious Skin Diseases
11. RESEARCH INTERVIEWS FROM OUR SURVEY
11.1 Interview with Dr Steven Feldmen, Director of the Psoriasis Treatment Center, Wake Forest University School of Medicine, Winston-Salem
11.1.1 Psoriasis: Unmet Patent Needs
11.1.2 Leading Dermatology Markets
11.1.3 Patient Adherence is Crucial
11.1.4 The Future of Biological Drug Treatments
11.1.5 Technological and Pipeline Developments
11.1.6 Challenges for Dermatologic Treatments
11.2 Interview with Professor Hermann Lьbbert, PhD, Chief Executive Officer, Biofrontera AG
11.2.1 Current State of the Dermatological Drug Market
11.2.2 Biofrontera and Dermatologic Drugs
11.2.3 Future Prospects for the Dermatological Drug Market
11.2.4 High Medical Need in Inflammatory Skin Diseases and Skin Cancers
11.2.5 Challenges Facing the Dermatologic Drug Market
11.2.6 Thoughts on Biologics, Small Molecule and Combination Therapies
12. CONCLUSIONS
12.1 The World Dermatological Drug Market Will Grow
12.2 The US Continues to Lead the World Dermatological Drug Market
12.3 Biologics - Leading the Psoriasis Market
12.4 Infectious Skin Diseases Market Remains Strong
12.5 Dermatological Drug Companies: Market Consolidation
12.6 Opportunities in the Dermatitis Market
12.7 Lifecycle Management in the Acne Market
12.8 Outlook for World Dermatological Drug Market 2013-2023
1.1 World Dermatological Drug Market: Overview of Findings
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods
2. INTRODUCTION TO DERMATOLOGICAL DISORDERS AND THEIR TREATMENTS
2.1 An Introduction to Dermatology
2.1.1 The Structure of the Skin, Hair and Nails
2.1.2 Sweat and Sebaceous Glands
2.2 Functions of the Skin
2.3 Common Skin Diseases
2.4 An Introduction to Acne Vulgaris
2.4.1 Causes of Acne
2.5 An Introduction to Dermatitis - Inflammation of the Skin
2.5.1 Atopic Dermatitis
2.5.2 Contact Dermatitis
2.5.3 Seborrheic Dermatitis
2.5.4 Nummular Dermatitis
2.5.5 Perioral Dermatitis
2.6 An Introduction to Psoriasis - A Complex Multifactorial Disease
2.7 An Introduction to Rosacea - Vascular Instability
2.8 An Introduction to Alopecia - The Excessive Shedding of Hair
2.9 An Introduction to Infectious Diseases of the Skin - A Serious Healthcare Threat
2.9.1 Bacterial Skin Infections
2.9.2 Fungal Skin Infections
2.9.3 Viral Skin Infections
2.10 Common Skin Treatments
2.10.1 Creams and Semisolid Emulsions
2.10.2 Ointments
2.10.3 Lotions
2.10.4 Solutions
2.10.5 Occlusive Therapy
2.10.6 Cleansing Agents
2.10.7 Powders and Hydrophilic Polymer
2.10.8 Anti-Infective Agents
2.10.9 Anti-Inflammatory Agents
3. THE WORLD DERMATOLOGICAL DRUG MARKET 2013-2023
3.1 The World Dermatological Drug Market 2011
3.1.1 The Infectious Skin Disease Market Dominates
3.2 The World Dermatological Drug Market: Forecasts 2012-2023
3.2.1 Market Shares for Leading Segments - Psoriasis Market Grows
3.2.2 Biologic Agents for the Treatment of Psoriasis Are the Leading Drugs in the Dermatologics Market
3.3 The Future of the Dermatological Drug Market
3.3.1 Opportunities for Blockbuster Sales
4. THE INFECTIOUS SKIN DISEASES DRUG MARKET 2013-2023
4.1 The Infectious Skin Diseases Drug Market 2011
4.1.1 Antibacterial Products Led the Dermatological Infectious Skin Diseases Market in 2011
4.2 World Infectious Skin Diseases Drug Market Forecast 2012-2023
4.3 Cubicin (Daptomycin, Cubist Pharmaceuticals)
4.3.1 Cubicin: Revenue Forecast 2012-2023
4.4 Zyvox (Linezolid, Pfizer)
4.4.1 Zyvox: Revenue Forecast 2012-2023
4.4.1.1 Zyvox: Patent Expiry and Generic Competition
4.5 Valtrex (Valacyclovir, GSK)
4.5.1 Patent Expiry and the End of Blockbuster Revenues
4.5.2 Valtrex Sales Continue to Decline - Increased Generic Competition
4.6 Zovirax (Acyclovir, Valeant/GSK)
4.6.1 Zovirax Sales Forecast 2012-2023
4.7 Bactroban (Mupirocin, GSK)
4.7.1 Bactroban Sales Forecast 2012-2023
4.8 Lamisil (Terbinafine, Novartis)
4.8.1 Lamisil Sales Forecast 2012-2023 - Growth in Emerging Markets
4.9 Aldara (Imiquimod, Valeant/Meda AB)
4.9.1 Reformulation and Zyclara Development
4.9.2 Aldara Sales Forecast, 2012-2023
4.10 The Infectious Skin Diseases Market - Summary
5. THE PSORIASIS DRUG MARKET 2013-2023
5.1 The Psoriasis Drug Market in 2011 - Biologic Drugs Led
5.1.1 Side-Effects of Biologics
5.2 World Psoriasis Drug Market Forecast 2012-2023
5.2.1 Growth Driven by Increasing Use of Biologics
5.3 Humira (Adalimumab, Abbott)
5.3.1 Humira Market Analysis and Forecast 2012-2023
5.3.2 Humira Sales Continue to Grow
5.3.3 Long-Term Prospects for Humira
5.4 Enbrel (Etanercept, Amgen/Pfizer/Takeda)
5.4.1 Enbrel Sales, 2011
5.4.2 Enbrel Sales Will Show an Initial Increase
5.4.3 Study Eases Fears of TNF Blocker Cancer Risk
5.4.4 New Enbrel Delivery System
5.4.5 Sales of Enbrel will Eventually Decline
5.4.6 Enbrel Faces Competition from Several Other Biotech Drugs
5.4.7 Biosimilar and Pipeline Competition
5.5 Stelara (Ustekinumab, Johnson & Johnson)
5.5.1 Stelara Advantages Promote Sales Growth
5.6 Remicade (Infliximab, Johnson & Johnson)
5.6.1 Remicade Psoriasis Market Forecast 2012-2023
5.7 Daivobet/Dovobet/Taclonex (Calcipotriol and Betamethasone, LEO Pharma) - Topical Treatments for Psoriasis
5.7.1 Daivobet/Dovobet/Taclonex - Generic Competition?
5.7.2 Daivobet Sales Prospects
5.8 The World Psoriasis Drug Market - Summary
6. THE DERMATITIS DRUG MARKET 2013-2023
6.1 The Dermatitis Drug Market in 2011
6.1.1 Corticosteroids are the Leading Dermatitis Treatment
6.2 Dermatitis Drug Market Forecast 2012-2023
6.3 Protopic (Tacrolimus, Astellas/Roche)
6.3.1 Protopic Sales Forecast 2012-2023
6.3.1.1 Protopic Benefits from Expanded Indication
6.3.1.2 Generic Competition Will Erode Sales
6.4 Elidel (Pimecrolimus, Novartis/Meda AB/Valeant)
6.4.1 Acquisition of Elidel Marketing Rights
6.4.2 Regulatory Developments
6.4.3 Elidel Sales Growth Stimulated
6.5 Elocon (Mometasone Furoate, Merck & Co.)
6.5.1 Elocon Sales Forecast 2012-2023
6.6 Clob X/Clobex (Clobetasol Propionate, Galderma)
6.6.1 Clobex Sales Face Generic Competition
6.7 The Dermatitis Drug Market - Summary
7. THE ACNE DRUG MARKET 2013-2023
7.1 Leading Products in the Acne Drug Market 2011
7.2 World Acne Drug Market Forecast 2012-2023
7.3 Claravis (Isotretinoin, Teva)
7.3.1 Claravis Sales Forecast 2012-2023
7.3.2 Competition from New Formulations
7.4 Solodyn (Minocycline, Valeant/Medicis)
7.4.1 Solodyn - A Leading Acne Treatment
7.4.2 Solodyn Sales Forecast 2012-2023
7.5 Diane (Cyproterone and Ethinylestradiol, Bayer): Market Analysis and Forecast 2012-2023
7.6 Duac (Clindamycin and Benzoyl Peroxide, GSK) - Generic Competition Erodes Sales
7.7 Doryx (Doxycycline Hyclate, Warner Chilcott/Mayne)
7.7.1 Lifecycle Management and Generic Competition
7.7.2 Doryx Sales Forecast 2012-2023
7.8 Differin (Adapalene, Galderma)
7.8.1 Lifecycle Management of Galderma's Adapalene Products
7.8.2 Differin Sales Forecast 2012-2023
7.9 Combination Treatments for Acne
7.10 Epiduo (Adapalene and Benzoyl Peroxide, Galderma)
7.10.1 Epiduo Forecast 2012-2023
7.11 Ziana (Tretinoin and Clindamycin, Valeant/Medicis)
7.12 Veltin (Tretinoin and Clindamycin, GSK)
7.13 The World Acne Drug Market - Summary
8. NATIONAL MARKET FORECASTS 2013-2023
8.1 Leading National Markets for Dermatological Drugs 2011
8.2 Leading National Markets for Dermatological Drugs: Forecasts 2012-2023
8.3 The Dermatological Drug Market in the US: Market Forecast 2012-2023
8.4 EU5 Dermatological Drug Markets 2012-2023
8.4.1 The Dermatological Drug Market in Germany: Market Forecast 2012-2023
8.4.2 The Dermatological Drug Market in France: Market Forecast 2012-2023
8.4.3 The Dermatological Drug Market in the UK: Market Forecast 2012-2023
8.4.4 The Dermatological Drug Market in Italy: Market Forecast 2012-2023
8.4.5 The Dermatological Drug Market in Spain: Market Forecast 2012-2023
8.5 The Dermatological Drug Market in Japan: Market Forecast 2012-2023
8.6 The Dermatological Drug Market in China: Market Forecast 2012-2023
8.7 The Dermatological Drug Market in India: Market Forecast 2012-2023
8.8 The Dermatological Drug Market in Russia: Market Forecast 2012-2023
8.9 The Dermatological Drug Market in Brazil: Market Forecast 2012-2023
9. THE R&D PIPELINE FOR DERMATOLOGICAL PHARMACEUTICALS, 2013
9.1The Size of the Dermatological Pharmaceuticals Market Encourages R&D
9.1.1 New Technology in R&D Pipeline Activities
9.1.2 Reformulation
9.1.3 Combination Treatments
9.1.4 New Mechanisms and Drug Delivery Technologies
9.1.5 Potential Market Entrants
9.2 The Infectious Skin Disease Pipeline
9.2.1 NB-001( NanoBio Corporation)
9.2.2 Dalbavancin (Durata Therapeutics) - Promising Anti-bacterial Skin Infection Treatment
9.2.3 Nuvocid (Oritavancin)
9.2.4 Tedizolid (Trius Therapeutics) - Driver for Growth
9.3 The Psoriasis Pipeline
9.3.1 Briakinumab (Abbott)
9.3.2 XelJanz (Tofacitinib, Pfizer) - Leading Oral Candidate
9.3.3 Voclosporin (VCS, ISA247, Isotechnika/Lux Biosciences) - Novel Calcineurin Inhibitor
9.3.4 Apremilast (Celgene) - The Next TNF Antagonist to be Approved?
9.3.5 AS101 (BioMAS)
9.3.6 AIN457 (Secukinumab, Novartis) - A New Mechanism of Action?
9.3.7 ASP015K (Astellas/Janssen Biotech)
9.4 The Dermatitis Pipeline
9.4.1 LAS41002 (Almirall) - European Approval?
9.4.2 AN2728 (Anacor Pharmaceuticals) - A Novel Small Molecule
9.4.3 MRX6 (Morria Biopharmaceuticals)
9.5 The Acne Pipeline
9.5.1 Visonac (PhotoCure) - Photodynamic Therapy
9.5.2 Acne Vaccine - A Treatment for the Future?
9.6 The Miscellaneous Dermatological Drugs Pipeline
9.6.1 LAS 41005 (Actikeral, Almirall) - European Launch
9.6.2 Picato (PEP005, LEO Pharma)
9.7 Innovation Rules for Early-Stage Pipeline Drugs
10. QUALITATIVE ANALYSIS OF THE WORLD DERMATOLOGICAL DRUG MARKET, 2013
10.1 SWOT Analysis
10.2 Market Drivers
10.3 Market Restraints
10.4 Strengths and Opportunities
10.4.1 Opportunities for Market Development and Expansion
10.4.2 Advances in Research Will Boost Market
10.4.3 What Benefits Can OTC Switching Offer?
10.4.4 Growth in Skin Structure Infection Therapeutics
10.4.5 The Challenge and Opportunity: Hospital-Acquired Infections
10.4.6 Targeting Drug-Resistant Bacteria in Infectious Skin Diseases
10.4.7 Opportunities for Speciality Pharma and Small Biotechs
10.4.8 CROs Can Increase Dermatological Drug Development Speed to Market
10.5 Weaknesses and Threats
10.5.1 Competition in the Dermatological Drug Market Will Intensify
10.5.2 Threat of Substitutes
10.5.3 How Great is the Threat of Generic Drugs in the Dermatological Sector?
10.5.4 Patent Expiries Will Lead to Generic Competition
10.5.5 Vaccines for Preventing Infections, Opportunity or Threat?
10.6 STEP Analysis
10.6.1 Social Factors
10.6.1.1 Increased Healthcare Demands
10.6.1.2 Improving Patient Compliance is Vital
10.6.2 Technological
10.6.2.1 Personalised Dermatology: Technological Advances in Genomics
10.6.2.2 Advances in Topical Drug Delivery Methods
10.6.3 Economic Pressures
10.6.3.1 Reimbursement will Continue to Slide
10.6.3.2 Cutting Back Pharma R&D
10.6.3.3 Public Funding for Infectious Skin Disease Drug Development
10.6.4 Political
10.6.4.1 Downward Pressures on Drug Prices Affect the Industry
10.6.4.2 Increased Development Funding in the US for Infectious Skin Diseases
11. RESEARCH INTERVIEWS FROM OUR SURVEY
11.1 Interview with Dr Steven Feldmen, Director of the Psoriasis Treatment Center, Wake Forest University School of Medicine, Winston-Salem
11.1.1 Psoriasis: Unmet Patent Needs
11.1.2 Leading Dermatology Markets
11.1.3 Patient Adherence is Crucial
11.1.4 The Future of Biological Drug Treatments
11.1.5 Technological and Pipeline Developments
11.1.6 Challenges for Dermatologic Treatments
11.2 Interview with Professor Hermann Lьbbert, PhD, Chief Executive Officer, Biofrontera AG
11.2.1 Current State of the Dermatological Drug Market
11.2.2 Biofrontera and Dermatologic Drugs
11.2.3 Future Prospects for the Dermatological Drug Market
11.2.4 High Medical Need in Inflammatory Skin Diseases and Skin Cancers
11.2.5 Challenges Facing the Dermatologic Drug Market
11.2.6 Thoughts on Biologics, Small Molecule and Combination Therapies
12. CONCLUSIONS
12.1 The World Dermatological Drug Market Will Grow
12.2 The US Continues to Lead the World Dermatological Drug Market
12.3 Biologics - Leading the Psoriasis Market
12.4 Infectious Skin Diseases Market Remains Strong
12.5 Dermatological Drug Companies: Market Consolidation
12.6 Opportunities in the Dermatitis Market
12.7 Lifecycle Management in the Acne Market
12.8 Outlook for World Dermatological Drug Market 2013-2023
LIST OF TABLES
Table 3.1 Dermatological Drug Revenue Forecasts by Submarket ($m), AGR (%), CAGR (%), 2011-2017
Table 3.2 Dermatological Drug Revenue Forecasts by Submarket ($m), AGR (%), CAGR (%), 2017-2023
Table 3.3 Dermatological Drugs: World Market Shares by Submarket (%), 2011, 2017 & 2023 Table 3.4 Leading Dermatological Drugs: Sales ($m), 2011
Table 4.1 Dermatological Drugs: Infectious Skin Disease Revenue Forecasts by Drug ($m), AGR (%), CAGR (%), 2011-2017
Table 4.2 Dermatological Drugs: Infectious Skin Disease Revenue Forecasts by Drug ($m), AGR (%), CAGR (%), 2017-2023
Table 4.3 Dermatological Drugs: Infectious Skin Disease Market Sales by Drug (%), 2011, 2017 & 2023
Table 4.4 Cubicin Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 4.5 Cubicin Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 4.6 Zyvox Key Facts, 2011
Table 4.7 Zyvox Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 4.8 Zyvox Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 4.9 Valtrex Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 4.10 Valtrex Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 4.11 Zovirax Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 4.12 Zovirax Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 4.13 Bactroban Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 4.14 Bactroban Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 4.15 Lamisil Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 4.16 Lamisil Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 4.17 Aldara Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 4.18 Aldara Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.1 Dermatological Drugs: Psoriasis Revenue Forecasts by Drug ($m), AGR (%), CAGR (%), 2011-2017
Table 5.2 Dermatological Drugs: Psoriasis Revenue Forecasts by Drug ($m), AGR (%), CAGR (%), 2017-2023
Table 5.3 Dermatological Drugs: Psoriasis Market Sales by Drug (%), 2011, 2017 & 2023
Table 5.4 Humira Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.5 Humira Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.6 Enbrel Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.7 Enbrel Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.8 Stelara Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.9 Stelara Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.10 Remicade Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.11 Remicade Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.12 Daivobet Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.13 Daivobet Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 6.1 Dermatological Drugs: Dermatitis Revenue Forecasts by Drug ($m), AGR (%), CAGR (%), 2011-2017
Table 6.2 Dermatological Drugs: Dermatitis Revenue Forecasts by Drug ($m), AGR (%), CAGR (%), 2017-2023
Table 6.3 Dermatological Drugs Dermatitis Market Sales by Drug (%), 2011, 2017 & 2023
Table 6.4 Protopic Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 6.5 Protopic Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 6.6 Elidel Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 6.7 Elidel Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 6.8 Elocon Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 6.9 Elocon Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 6.10 Clobex Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 6.11 Clobex Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 7.1 Dermatological Drugs: Acne Revenue Forecasts by Drug ($m), AGR (%), CAGR (%), 2011-2017
Table 7.2 Dermatological Drugs: Acne Revenue Forecasts by Drug ($m), AGR (%), CAGR (%), 2017-2023
Table 7.3 Dermatological Drugs Acne Market Sales by Drug (%), 2011, 2017 & 2023
Table 7.4 Claravis Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 7.5 Claravis Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 7.6 Solodyn Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 7.7 Solodyn Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 7.8 Diane Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 7.9 Diane Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 7.10 Duac Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 7.11 Duac Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 7.12 Doryx Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 7.13 Doryx Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 7.14 Differin Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 7.15 Differin Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 7.16 Epiduo Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 7.17 Epiduo Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.1 Dermatological Drug Revenue Forecasts by Region ($m), AGR (%), CAGR (%), 2011-2017
Table 8.2 Dermatological Drug Revenue Forecasts by Region ($m), AGR (%), CAGR (%), 2017-2023
Table 8.3 Dermatological Drugs: World Market Shares by Region (%), 2011, 2017 & 2023
Table 8.4 The US Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.5 The US Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.6 EU5 Dermatological Drug Revenue Forecasts ($m), AGR (%), CAGR (%), 2011-2017
Table 8.7 EU5 Dermatological Drugs Revenue Forecasts ($m), AGR (%), CAGR (%), 2017-2023
Table 8.8 Dermatological Drugs: EU5 Market Shares by Region (%), 2011, 2017 & 2023
Table 8.9 The German Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.10 The German Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.11 The French Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.12 The French Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.13 The UK Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.14 The UK Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.15 The Italian Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.16 The Italian Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.17 The Spanish Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.18 The Spanish Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.19 The Japanese Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.20 The Japanese Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.21 The Chinese Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.22 The Chinese Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.23 The Indian Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.24 The Indian Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.25 The Russian Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.26 The Russian Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.27 The Brazilian Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.28 The Brazilian Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 9.1 Pipeline for Infectious Skin Disease Drugs, 2013
Table 9.2 Pipeline for Psoriasis Drugs, 2013
Table 9.3 Pipeline for Dermatitis Drugs, 2013
Table 9.4 Pipeline for Acne Drugs, 2013
Table 9.5 Pipeline for Other Dermatological Drugs, 2013
Table 10.1 SWOT Analysis of the Dermatological Drug Market, 2013
Table 10.2 Recent and Future OTC Switches
Table 3.1 Dermatological Drug Revenue Forecasts by Submarket ($m), AGR (%), CAGR (%), 2011-2017
Table 3.2 Dermatological Drug Revenue Forecasts by Submarket ($m), AGR (%), CAGR (%), 2017-2023
Table 3.3 Dermatological Drugs: World Market Shares by Submarket (%), 2011, 2017 & 2023 Table 3.4 Leading Dermatological Drugs: Sales ($m), 2011
Table 4.1 Dermatological Drugs: Infectious Skin Disease Revenue Forecasts by Drug ($m), AGR (%), CAGR (%), 2011-2017
Table 4.2 Dermatological Drugs: Infectious Skin Disease Revenue Forecasts by Drug ($m), AGR (%), CAGR (%), 2017-2023
Table 4.3 Dermatological Drugs: Infectious Skin Disease Market Sales by Drug (%), 2011, 2017 & 2023
Table 4.4 Cubicin Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 4.5 Cubicin Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 4.6 Zyvox Key Facts, 2011
Table 4.7 Zyvox Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 4.8 Zyvox Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 4.9 Valtrex Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 4.10 Valtrex Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 4.11 Zovirax Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 4.12 Zovirax Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 4.13 Bactroban Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 4.14 Bactroban Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 4.15 Lamisil Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 4.16 Lamisil Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 4.17 Aldara Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 4.18 Aldara Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.1 Dermatological Drugs: Psoriasis Revenue Forecasts by Drug ($m), AGR (%), CAGR (%), 2011-2017
Table 5.2 Dermatological Drugs: Psoriasis Revenue Forecasts by Drug ($m), AGR (%), CAGR (%), 2017-2023
Table 5.3 Dermatological Drugs: Psoriasis Market Sales by Drug (%), 2011, 2017 & 2023
Table 5.4 Humira Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.5 Humira Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.6 Enbrel Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.7 Enbrel Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.8 Stelara Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.9 Stelara Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.10 Remicade Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.11 Remicade Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.12 Daivobet Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.13 Daivobet Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 6.1 Dermatological Drugs: Dermatitis Revenue Forecasts by Drug ($m), AGR (%), CAGR (%), 2011-2017
Table 6.2 Dermatological Drugs: Dermatitis Revenue Forecasts by Drug ($m), AGR (%), CAGR (%), 2017-2023
Table 6.3 Dermatological Drugs Dermatitis Market Sales by Drug (%), 2011, 2017 & 2023
Table 6.4 Protopic Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 6.5 Protopic Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 6.6 Elidel Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 6.7 Elidel Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 6.8 Elocon Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 6.9 Elocon Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 6.10 Clobex Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 6.11 Clobex Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 7.1 Dermatological Drugs: Acne Revenue Forecasts by Drug ($m), AGR (%), CAGR (%), 2011-2017
Table 7.2 Dermatological Drugs: Acne Revenue Forecasts by Drug ($m), AGR (%), CAGR (%), 2017-2023
Table 7.3 Dermatological Drugs Acne Market Sales by Drug (%), 2011, 2017 & 2023
Table 7.4 Claravis Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 7.5 Claravis Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 7.6 Solodyn Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 7.7 Solodyn Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 7.8 Diane Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 7.9 Diane Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 7.10 Duac Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 7.11 Duac Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 7.12 Doryx Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 7.13 Doryx Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 7.14 Differin Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 7.15 Differin Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 7.16 Epiduo Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 7.17 Epiduo Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.1 Dermatological Drug Revenue Forecasts by Region ($m), AGR (%), CAGR (%), 2011-2017
Table 8.2 Dermatological Drug Revenue Forecasts by Region ($m), AGR (%), CAGR (%), 2017-2023
Table 8.3 Dermatological Drugs: World Market Shares by Region (%), 2011, 2017 & 2023
Table 8.4 The US Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.5 The US Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.6 EU5 Dermatological Drug Revenue Forecasts ($m), AGR (%), CAGR (%), 2011-2017
Table 8.7 EU5 Dermatological Drugs Revenue Forecasts ($m), AGR (%), CAGR (%), 2017-2023
Table 8.8 Dermatological Drugs: EU5 Market Shares by Region (%), 2011, 2017 & 2023
Table 8.9 The German Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.10 The German Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.11 The French Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.12 The French Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.13 The UK Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.14 The UK Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.15 The Italian Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.16 The Italian Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.17 The Spanish Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.18 The Spanish Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.19 The Japanese Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.20 The Japanese Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.21 The Chinese Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.22 The Chinese Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.23 The Indian Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.24 The Indian Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.25 The Russian Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.26 The Russian Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 8.27 The Brazilian Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 8.28 The Brazilian Dermatological Drugs Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 9.1 Pipeline for Infectious Skin Disease Drugs, 2013
Table 9.2 Pipeline for Psoriasis Drugs, 2013
Table 9.3 Pipeline for Dermatitis Drugs, 2013
Table 9.4 Pipeline for Acne Drugs, 2013
Table 9.5 Pipeline for Other Dermatological Drugs, 2013
Table 10.1 SWOT Analysis of the Dermatological Drug Market, 2013
Table 10.2 Recent and Future OTC Switches
Daivobet/Dovobet/Taclonex (Calcipotriol and Betamethasone, LEO Pharma) – Topical Treatments for PsoriasisMost patients who have mild psoriasis are treated with topical therapies. The most common of these are topical corticosteroids and vitamin D analogues. The majority of prescriptions written for psoriasis are for topical therapies. In moderate-to-severe psoriasis, however, those treatments areapparently inconvenient, which has led to increase prescribing of biologic systemic therapies. Over 50% of severe psoriasis patients in the US are apparently prescribed a systemic therapy.Daivobet/Dovobet/Taclonex (calcipotriol and betamethasone).
LEO Pharma’s Daivobet is a topical psoriasis treatment which combines the vitamin D analogue calcipotriol with the steroid betamethasone. LEO Pharma currently produces a variety ofcalcipotriol and betamethasone formulations, including an ointment, gel and topical suspensions. Launched in Canada and Denmark in 2001, is it now available in over 40 countries. In some countries (including the UK), it is marketed as Dovobet. In 2006, licensee Warner Chilcott launched the product in the US branded Taclonex. LEO Pharma apparently re-acquired the US marketing rights to the drug from Warner Chilcott in 2009. As of 30th June 2010, LEO assumed responsibility for its own distribution services. LEO Pharma has reportedly been active in the lifecycle management of Daivobet, launching a gel formulation in July 2010. A gel formulation for scalp psoriasis has also been launched, and is marketed in the US as Taclonex Scalp, and in European markets and Canada as Xamiol. However, in May 2012 the company apparently discontinued manufacturing Xamiol. The company explained that Xamiol gel and Dovobet gel both have the same formulation; however Xamiol was only licensed for use on the scalp, whereas Dovobet Gel is licensed to treat mild to moderate body psoriasis and scalp psoriasis. In addition, the US (FDA) approved Taclonex topical suspension, 0.005%/0.064% for the treatment of body plaque psoriasis in October 2012.
Taclonex is now sold in the US by LEO Pharma’s new US subsidiary. Active marketing efforts for Taclonex and other dermatology products are expected to cement the new company’s presence in the market.
Daivobet/Dovobet/Taclonex – Generic Competition?
On February 22, 2011, Perrigo announced their filing of an ANDA for generic Taclonex. LEO Pharma apparently filed a suit claiming patent infringement, triggering a 30-month stay for litigation. Visiongain notes that patents protecting Taclonex expire in 2015 and 2020, the laterpatent expiry covering use for treating psoriasis and moderate plaque psoriasis.
